Literature DB >> 12832947

Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice.

Shubulade Smith1.   

Abstract

Typical antipsychotic agents are commonly associated with hyperprolactinemia, which, in turn, leads to sexual dysfunction. The mechanism of action underlying this clinical phenomenon is mediated by the dopamine-blocking action of typical antipsychotic medications, which results in excessive prolactin secretion and secondary effects on gonadal function. This antipsychotic-induced sexual dysfunction is unacceptable to patients and is associated with nonadherence to medication, impacting on the overall clinical outcome and treatment success. Development of first-line atypical antipsychotic agents that do not affect prolactin production is therefore an important advance for patients requiring long-term antipsychotic therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832947     DOI: 10.1097/01.jcp.0000084035.22282.31

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  Ziprasidone-induced galactorrhea in an adolescent female: a case report.

Authors:  Shakeel Raza; Fasiha Haq
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Sexual dysfunction in male subjects receiving trifluoperazine, risperidone, or olanzapine: rates vary with assessment questionnaire.

Authors:  Naresh Nebhinani; Sandeep Grover; Ajit Avasthi
Journal:  Prim Care Companion CNS Disord       Date:  2012-04-26

3.  Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial.

Authors:  Ahmed Mahmoud; Karen P Hayhurst; Richard J Drake; Shôn W Lewis
Journal:  Schizophr Res Treatment       Date:  2011-01-16

Review 4.  Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications.

Authors:  Amber N Edinoff; Nancy S Silverblatt; Hayley E Vervaeke; Cassidy C Horton; Eden Girma; Alan D Kaye; Adam Kaye; Jessica S Kaye; Andrew J Garcia; Elisa E Neuchat; Treniece N Eubanks; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16

5.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.